Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Cost of Revenue: 2022-2025

Historic Cost of Revenue for Whitehawk Therapeutics (WHWK) over the last 3 years, with Mar 2025 value amounting to $760,000.

  • Whitehawk Therapeutics' Cost of Revenue rose 16.56% to $760,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $3.1 million, marking a year-over-year increase of 6.82%. This contributed to the annual value of $3.0 million for FY2024, which is 7.65% up from last year.
  • As of Q1 2025, Whitehawk Therapeutics' Cost of Revenue stood at $760,000, which was down 3.80% from $790,000 recorded in Q4 2024.
  • In the past 5 years, Whitehawk Therapeutics' Cost of Revenue ranged from a high of $927,000 in Q4 2023 and a low of $179,000 during Q1 2022.
  • Over the past 3 years, Whitehawk Therapeutics' median Cost of Revenue value was $760,000 (recorded in 2025), while the average stood at $732,556.
  • In the last 5 years, Whitehawk Therapeutics' Cost of Revenue surged by 317.57% in 2023 and then fell by 14.78% in 2024.
  • Whitehawk Therapeutics' Cost of Revenue (Quarterly) stood at $222,000 in 2022, then skyrocketed by 317.57% to $927,000 in 2023, then fell by 14.78% to $790,000 in 2024, then climbed by 16.56% to $760,000 in 2025.
  • Its Cost of Revenue was $760,000 in Q1 2025, compared to $790,000 in Q4 2024 and $804,000 in Q3 2024.